AIM

AIM ImmunoTech Inc
AMEX

实时行情|Nasdaq Last Sale

2.040
-0.010
-0.49%
盘后: 2.120 +0.08 +3.92% 19:24 03/27 EDT
开盘
2.010
昨收
2.050
最高
2.100
最低
1.900
成交量
204.63万
成交额
--
52周最高
14.81
52周最低
0.3810
市值
5,215.32万
市盈率(TTM)
-0.3105
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测AIM价格均价为3.833,最高价位6.50,最低价为2.000。

EPS

AIM 新闻

更多
  • NRZ, TLRY among premarket gainers
  • Seeking Alpha - Article · 2天前
  • AIM ImmunoTech Announces Further Efforts to Establish Clinical Trials Assessing Ampligen as a Potential Protective and Early-Onset Treatment for the Current COVID-19 Pandemic
  • ACCESSWIRE · 2天前
  • SLS, APRN among premarket gainers
  • Seeking Alpha - Article · 03/18 13:23
  • Coronavirus plays on the move premarket
  • Seeking Alpha - Article · 03/16 11:43

所属板块

生物技术和医学研究
-2.43%
制药与医学研究
-0.87%

热门股票

代码
价格
涨跌幅

AIM 简况

AIM ImmunoTech Inc., formerly Hemispherx Biopharma, Inc., is a specialty pharmaceutical company. The Company is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company's segment is engaged in research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon. The Company's products include Alferon N Injection and Ampligen. Alferon N Injection is approved for the use in intralesional treatment of refractory or recurring external genital warts in patients of over 18 years of age. Ampligen is a drug undergoing clinical development for the treatment of Chronic Fatigue Syndrome (CFS). Alferon LDO (Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)) is a low-dose, oral liquid formulation of natural alpha interferon. Alferon LDO is a liquid natural interferon for oral administration.
展开

微牛提供AIM ImmunoTech Inc(AMEX-AIM)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的AIM股票新闻,以帮助您做出投资决策。